{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-008399","form_type":"8-K","ticker":null,"cik":"0001183765","company_name":"Molecular Templates, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.103041+00:00","generated_at":"2026-05-26T03:20:43.021868+00:00","sec_items":["1.01","2.03","3.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Molecular Templates gets $560K bridge loan at 13.5% due April 2025; warns no value for shareholders","bullets":["Initial Bridge Loan of $560,000 at 13.5% fixed interest, matures April 21, 2025.","Loan secured by first-priority lien on substantially all assets, including IP.","Amended CVR agreement sets repayment maturity at February 1, 2026.","Company cautions trading is highly speculative, does not expect holders to receive value.","Company does not expect to have resources to continue SEC reporting obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-008399","json":"https://secwatch.observer/filing/0001493152-25-008399.json","markdown":"https://secwatch.observer/filing/0001493152-25-008399.md","text":"https://secwatch.observer/filing/0001493152-25-008399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1183765/000149315225008399/0001493152-25-008399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1183765/000149315225008399/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:20:43.021868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e05e89253979905ec1bff47be49b752a158e73a","claim":"Molecular Templates, Inc. incurred loan of $560,000 with K2 HealthVentures LLC at 13.5% per annum maturing April 21, 2025.","evidence_excerpt":"Lenders, Collateral Trustee, and Administrative Agent. Amount . Pursuant to the Loan and Security Agreement, the Lenders agreed to extend to the Company (i) an initial loan of $560,000 which was drawn on the closing date (the “Initial Bridge Loan”) and (ii) subject to Lenders’ approval in each Lender’s sole and absolute discretion and the terms and conditions of","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1183765/000149315225008399/0001493152-25-008399-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$560,000"},{"label":"Counterparty","value":"K2 HealthVentures LLC"},{"label":"Rate","value":"13.5% per annum"},{"label":"Maturity","value":"April 21, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}